Table 1 Number of patients analyzed
From: Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
Year | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Diabetics patients followed up (1) | 19,005 | 20,434 | 21,512 | 22,566 | 23,713 | 24,862 | ||||||
Patients analyzed | 9,682 | 10,397 | 11,094 | 11,772 | 11,583 | 9,734 | ||||||
Monotherapy | 5,792 | 59.8% | 5,890 | 56.7% | 6,080 | 54.8% | 6,390 | 54.3% | 6,065 | 52.4% | 4,764 | |
Double therapy | 2,484 | 25.7% | 2,815 | 27.1% | 3,029 | 27.3% | 3,147 | 26.7% | 3,100 | 26.8% | 2,770 | 28.5% |
Triple therapy | 355 | 3.7% | 447 | 4.3% | 551 | 5.0% | 657 | 5.6% | 730 | 6.3% | 803 | 8.2% |
Polytherapy | 14 | 0.1% | 28 | 0.3% | 44 | 0.4% | 66 | 0.6% | 73 | 0.6% | 98 | 1.0% |
Insulinotherapy | 1,037 | 10.7% | 1,217 | 11.7% | 1,390 | 12.5% | 1,512 | 12.8% | 1,615 | 13.9% | 1,299 | 13.3% |
Patients excluded | 9,323 | 10,037 | 10,418 | 10,794 | 12,130 | 15,128 | ||||||
Lost to follow up | 4,562 | 49% | 4,877 | 49% | 4,909 | 47% | 4,821 | 45% | 4,923 | 41% | 4,418 | 29% |
No pharmacological treatment | 839 | 9% | 1,152 | 11% | 1,466 | 14% | 1,719 | 16% | 2,008 | 17% | 1,610 | 11% |
Pharmacological treatment with: | ||||||||||||
Discontinuation period | 1,692 | 18% | 1,846 | 18% | 1,907 | 18% | 1,959 | 18% | 2,535 | 21% | 6,411 | 42% |
Non stationary period | 1,255 | 13% | 1,070 | 11% | 1,086 | 10% | 1,225 | 11% | 1,432 | 12% | 1,978 | 13% |
Stage changes | 975 | 10% | 1,092 | 11% | 1,050 | 10% | 1,070 | 10% | 1,232 | 10% | 711 | 5% |